Rf. Van Vollenhoven et al., VH4-34 encoded antibodies in systemic lupus erythematosus: A specific diagnostic marker that correlates with clinical disease characteristics, J RHEUMATOL, 26(8), 1999, pp. 1727-1733
Objective, To determine the clinical significance of elevated serum levels
of VH4-34 encoded antibodies (VH4-34 Ab) with respect to the diagnosis and
clinical characteristics of systemic lupus erythematosus (SLE),
Methods, Ninety-five patients with SLE and 344 controls were studied. The c
ontrols included 34 healthy individuals, 282 patients with nonautoimmune di
seases, and 28 patients with autoimmune diseases other than SLE. VH4-34 Ab
levels were measured by inhibition ELISA using anti-idiotope monoclonal ant
ibody (9G4). SLE disease activity, severity, and damage were assessed by vi
sual analog scales, Systemic Lupus Activity Measure, Lupus Severity of Dise
ase Index, and Systemic Lupus International Collaborating Clinics/American
College of Rheumatology Damage Index.
Results. Fifty-two of 95 patients with SLE had elevated levels of VH4-34 Ab
compared to 18 of 344 controls (5%), giving a sensitivity of 55% and a spe
cificity of 95% for elevated VH4-34, Ab as a serologic test for SLE. The po
sitive predictive value of elevated VH4-34 under these conditions was 74-85
%. In this study, anti-dsDNA was not VH4-34 encoded. Significant correlatio
ns between VH4-34 and disease activity and severity indices were observed (
r = 0.29-0.50). The relative risk for severe disease in SLE patients with V
H4-34 antibody level in the highest tertile compared to the lowest tertile
was 5.25. Twenty-five of 29 patients with lupus nephritis and 6 of 6 patien
ts with central nervous system (CNS) lupus had elevated VH4-34 Ab.
Conclusion. With a specificity of 94-95%, the VH4-34 antibody assay may pro
ve valuable as a confirmatory diagnostic test for SLE. In patients with kno
wn SLE, serum VH4-34 Ab levels correlate with overall disease severity and
activity, but not damage, and with nephritis and CNS lupus.